Pre-clinical and clinical studies of therapeutic antibodies require highly specific reagents to examine their immune responses, bio-distributions, immunogenicity, and pharmacodynamics in patients. Selective antigen-mimicking anti-idiotype antibody facilitates the assessment of therapeutic antibody in the detection, quantitation and characterization of antibody immune responses. Using mouse spec...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

Abstract The IL-1 family receptor antagonist IL-38 suppresses auto-inflammatory reactions in murine disease models. Given the connection between auto-immunity and anti-tumor immunity, we wondered if targeting would affect latter. transgenic PyMT mammary carcinoma model was employed to target genetically or with a neutralizing antibody. IL-38-deficient (KO) mice had markedly delayed tumor growth...

Antibodies are well known for their high specificity that has enabled them to be of significant use in both therapeutic and diagnostic applications. can recognize different antigens, including proteins, carbohydrates, peptides, nucleic acids, lipids, small molecular weight haptens abundantly available as hormones, pharmaceuticals, pesticides. Here we focus on a structural analysis hapten-antibo...

Antibody recruiting molecules (ARMs) represent an important class of chemical tools with therapeutic potential. ARMs function by simultaneously binding to a hapten specific serum antibody (Ab) and cancer cell surface protein, thereby forming ARM:Ab complexes on the surface. These activate immune recognition elimination cell. Problematically, ARM in human patients may be limited conditions that ...